|
DE2847693A1
(de)
*
|
1978-11-03 |
1980-05-22 |
Hoechst Ag |
Verfahren zur herstellung von pyrimido-(6,1-a)-isochinolin-2-onen
|
|
US4625026A
(en)
*
|
1982-12-30 |
1986-11-25 |
Biomeasure, Inc. |
2-amino-4-oxo-tricyclicpyrimidines having antiviral activities against herpes simplex virus type II infections
|
|
US4814335A
(en)
*
|
1982-12-30 |
1989-03-21 |
Biomeasure, Incorporated |
Antiviral compounds
|
|
JPS6442472A
(en)
*
|
1987-08-10 |
1989-02-14 |
Kanebo Ltd |
Quinazoline derivative, production thereof and brain function disorder improving agent containing said derivative as active ingredient
|
|
US4877790A
(en)
*
|
1987-12-15 |
1989-10-31 |
Kanebo Limited |
Quinazoline derivative, processes for its production, and cerebral dysfunction remedying agent comprising it as active ingredient
|
|
TW334434B
(en)
*
|
1995-05-16 |
1998-06-21 |
Kanebo Ltd |
Novel quinazoline compound and anti-tumor agent
|
|
AU2769897A
(en)
*
|
1996-05-07 |
1997-11-26 |
Basf Aktiengesellschaft |
Imidazoquinazolines, agents containing them and their use to combat fungi and animal pests
|
|
US6900220B2
(en)
|
2001-01-02 |
2005-05-31 |
Syntex (U.S.A.) Llc |
Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
|
|
MXPA03005854A
(es)
*
|
2001-01-02 |
2003-09-10 |
Hoffmann La Roche |
Derivados de quinazolona como antagonistas del receptor adrenergico alfa 1a/b.
|
|
CN1209392C
(zh)
*
|
2001-05-14 |
2005-07-06 |
阿姆诺洼化学有限公司 |
由含侧氟碳基的环状单体得到的聚合物表面活性剂
|
|
EP1407774A1
(en)
*
|
2002-09-10 |
2004-04-14 |
LION Bioscience AG |
2-Amino-4-quinazolinones as LXR nuclear receptor binding compounds
|
|
EP1398032A1
(en)
*
|
2002-09-10 |
2004-03-17 |
PheneX Pharmaceuticals AG |
4-Oxo-quinazolines as LXR nuclear receptor binding compounds
|
|
WO2004031171A1
(ja)
|
2002-10-01 |
2004-04-15 |
Mitsubishi Pharma Corporation |
イソキノリン化合物及びその医薬用途
|
|
TW200412959A
(en)
|
2002-11-22 |
2004-08-01 |
Mitsubishi Pharma Corp |
Isoquinoline compounds and medicinal use thereof
|
|
SG150533A1
(en)
|
2003-11-20 |
2009-03-30 |
Janssen Pharmaceutica Nv |
6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2- quinoxalinones as poly(adp-ribose) polymerase inhibitors
|
|
WO2005054209A1
(en)
|
2003-11-20 |
2005-06-16 |
Janssen Pharmaceutica N.V. |
7-phenylalkyl substituted 2-quinolinones and 2 quinoxalinones as poly(adp-ribose) polymerase inhibitors
|
|
BRPI0512797A
(pt)
|
2004-06-30 |
2008-04-08 |
Janssen Pharmaceutica Nv |
derivados de quinazolinona como inibidores de parp
|
|
EP1763523B1
(en)
|
2004-06-30 |
2013-03-20 |
Janssen Pharmaceutica NV |
Quinazolinedione derivatives as parp inhibitors
|
|
CN1980674B
(zh)
|
2004-06-30 |
2011-05-25 |
詹森药业有限公司 |
作为parp抑制剂的2,3-二氮杂萘衍生物
|
|
EP1854795B1
(en)
*
|
2005-02-18 |
2016-06-01 |
Mitsubishi Tanabe Pharma Corporation |
Salt of a proline derivative, solvate thereof, and production method thereof
|
|
PL2007752T3
(pl)
|
2006-03-31 |
2011-02-28 |
Janssen Pharmaceutica Nv |
Benzoimidazol-2-ilopirymidyny i pirazyny jako modulatory receptora histaminowego H4
|
|
SI2134691T1
(sl)
|
2007-03-08 |
2012-06-29 |
Janssen Pharmaceutica Nv |
Derivati kvinolina kot PARP in TANK inhibitorji
|
|
US8404713B2
(en)
|
2007-10-26 |
2013-03-26 |
Janssen Pharmaceutica Nv |
Quinolinone derivatives as PARP inhibitors
|
|
HRP20150139T1
(hr)
|
2008-03-27 |
2015-05-22 |
Janssen Pharmaceutica N.V. |
Tetrahidrofenanthridinoni i tetrahidrociklopentakinolinoni kao inhibitori parp i polimerizacije tubulina
|
|
EP2260026B1
(en)
|
2008-03-27 |
2011-06-22 |
Janssen Pharmaceutica, N.V. |
Quinazolinone derivatives as tubulin polymerization inhibitors
|
|
TW201018668A
(en)
*
|
2008-06-30 |
2010-05-16 |
Janssen Pharmaceutica Nv |
Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives
|
|
US9371311B2
(en)
|
2008-06-30 |
2016-06-21 |
Janssen Pharmaceutica Nv |
Benzoimidazol-2-yl pyrimidine derivatives
|
|
EP2376495A4
(en)
|
2008-12-08 |
2012-10-31 |
Vm Pharma Llc |
COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS
|
|
WO2011086584A2
(en)
*
|
2010-01-18 |
2011-07-21 |
Msn Laboratories Limited |
Improved process for the preparation of amide intermediates and their use thereof
|
|
US9708300B2
(en)
*
|
2011-03-20 |
2017-07-18 |
Cadila Healthcare Limited |
Amorphous form of vilazodone hydrochloride and process for its preparation
|
|
DE102011113749A1
(de)
*
|
2011-09-14 |
2013-03-14 |
Aicuris Gmbh & Co. Kg |
Sulfonsäuresalze Heterocyclylamid-substituiertr Imidazole
|
|
CN104271573A
(zh)
*
|
2011-09-30 |
2015-01-07 |
詹森药业有限公司 |
(1-(4-氟苯基)-1h-吲哚-5-基)-(3-(4-(噻唑-2-羰基)哌嗪-1-基)氮杂环丁-1-基)甲酮的结晶盐酸盐及其治疗疼痛和代谢紊乱的用途
|
|
PT2825042T
(pt)
|
2012-03-15 |
2018-11-16 |
Celgene Car Llc |
Sais de um inibidor de cinases do recetor do fator de crescimento epidérmico
|
|
MY169233A
(en)
*
|
2012-03-15 |
2019-03-19 |
Celgene Car Llc |
Solid forms of an epidermal growth factor receptor kinase inhibitor
|
|
US20130261134A1
(en)
*
|
2012-03-30 |
2013-10-03 |
Boehringer Ingelheim International Gmbh |
Mesylate salt forms of a potent hcv inhibitor
|
|
PE20151274A1
(es)
|
2013-02-08 |
2015-09-12 |
Celgene Avilomics Res Inc |
Inhibidores de erk y sus usos
|
|
SMT202000084T1
(it)
|
2013-03-06 |
2020-03-13 |
Janssen Pharmaceutica Nv |
Modulatori benzoimidazol-2-il pirimidinici del recettore h4 dell'istamina
|
|
US8999992B2
(en)
*
|
2013-03-15 |
2015-04-07 |
Vm Pharma Llc |
Crystalline forms of tryosine kinase inhibitors and their salts
|
|
CA2932560C
(en)
*
|
2013-12-03 |
2022-11-15 |
Amgen Inc. |
Crystalline forms of n-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine pharmaceutically acceptable salts and uses thereof
|
|
DK3179858T3
(da)
|
2014-08-13 |
2019-07-22 |
Celgene Car Llc |
Forme og sammensætninger af en ERK-inhibitor
|
|
WO2016043975A1
(en)
|
2014-09-17 |
2016-03-24 |
Vm Pharma Llc |
Crystalline forms of tyrosine kinase inhibitors and their salts
|
|
CA3016092C
(en)
*
|
2016-03-22 |
2025-03-11 |
Jiangsu Hansoh Pharmaceutical Group Co Ltd |
POLYCRYSTALLINE FORM OF FREE BASIC OR SALT EGFR INHIBITOR ACID, PROCESS FOR ITS PREPARATION AND APPLICATION
|